One of the multi-bagger stocks that the Indian stock market has produced recently is Artemis Medicare Services shares. The value of this hospital stock has increased by 1000 per cent in around four and a half years, from ₹22.60 to ₹250 per share. The multi-bagger stock does, however, still have some upward potential. Today, the share price of Artemis Medicare Services opened the day higher, at ₹249, and reached a high of ₹259.90, up around 5% from Thursday’s closing price of ₹246.75 per share. The multibagger stock reached a high of ₹270 per share, its lifetime high, while also rising to an intraday high. The hospital’s stock saw significant buying following the release of its Q1 2024 results on Thursday.
Q1FY25
On Thursday, Artemis Medicare Services Ltd. released its Q1 FY25 financial results. The company runs 713 beds, mostly in the Delhi NCR area. This includes five hospitals operating under the Artemis Lite and Daffodils brands, a super speciality hospital accredited by JCI and NABH, and 541 beds for quaternary care. In addition, the company has a joint venture with Philips to operate seven centres under the Artemis Cardiac Care brand. With a management and operations agreement, Artemis is also present abroad in Mauritius.
Q1 results 2024
- Net Revenue from Operations rose from INR 2,095 Mn to INR 2,232 Mn, a 6.5% rise.
- From INR 292 million to INR 406 million, EBITDA climbed by 39%.
- At 18.2%, the EBITDA margin is higher than the consolidated figure of 13.9%.
- With a margin of 9.7%, the consolidated PBT climbed from INR 131 Mn to INR 216 Mn, a 65.1% gain.
- With a 7.4% margin, consolidated PAT climbed by 69.5% to INR 165 Mn from INR 98 Mn.
Devlina Chakravarty, Managing Director of Artemis Medicare Services, commented on the Q1 results 2024, saying, “Our robust performance of Q1 FY25 reflects our conscious efforts towards streamlining all the financial and operational metrics. This is one of our best-ever quarterly performances with our highest-ever ARPOB and EBITDA, giving a promising start to the year despite being a seasonally muted quarter. We have focussed on leveraging cost efficiencies and optimising asset utilisation, reflected in our highest EBITDA margins.”
